New Vaccines Approved for Use in 2017
By Luis G. de Jesus, MD
Hepatitis B Vaccine recombinant
Indication: Prevention of Hepatitis B infection for adults 18 years of age or older
Dosing: 2 doses, 1 month apart
Advantages: (compared to older vaccines)
- Two-dose hepatitis B vaccine for adults (instead of three doses)
- Higher rate of protection (95% vs. 81%).
- Promising vaccine for “non-responders” to older Hepatitis B vaccines (awaiting studies).
Zoster Vaccine recombinant
Indication: Prevention of herpes zoster (shingles) in adults aged 50 years and older
Dosing: 2 doses, 2-6 months apart
Advantages: (compared to older vaccine)
- Higher efficacy (90%) across all age groups).
- Provides longer and more persistent protection.
- Not a “live-virus” vaccine thus a promising vaccine for patients with weakened immune (awaiting studies).